AI Makes the Product. Talent Makes the Company.

Rock Health retired its "AI deal" tracking this quarter [1]. The reason: AI has become table stakes in how digital health companies are built and delivered. That single editorial decision tells you more about where healthcare investing is headed than any pitch deck.

The implication is stark. If every company is an AI company, then AI is no longer a differentiator. And if the product moat is shrinking, the question every CEO, board member, and investor needs to answer is: what's left?

Our answer: talent. Specifically, the leadership teams that decide what to build, how to sell it into an unforgiving regulatory environment, and when to say no.

The Commoditization Engine Is Running

Look at the money flowing into healthcare admin automation this month alone. Commure raised $70 million at a $7 billion valuation; its agentic AI now completes more than 85% of revenue cycle work without human intervention across 500-plus healthcare organizations [2]. Lassie closed a $35 million Series A for insurance workflow automation across 700-plus practices [3]. Yuzu Health pulled in $35 million to modernize TPA infrastructure [4]. Abridge, which started as an ambient documentation tool, expanded into claims management, coding, and prior authorization, with a strategic investment from Eli Lilly [5]. XCaliber Health raised $6.5 million for its own agentic AI platform targeting administrative burden [4].

The pattern is unmistakable: capital is flooding into companies that automate the same workflows. The tools are converging. When Commure's CEO says that "for thirty years, healthcare was told software would fix administrative work" and "AI can" [2], he's describing a technology shift that will, within a few years, be available to every health system with an Azure subscription or an API key.

Flare Capital Partners captured the dynamic precisely: the race healthcare AI companies are running is one "to establish new product beachheads sooner than existing ones become commodified" [6]. That's the treadmill. The product advantage is temporary. The question is what remains when the treadmill stops.

What Remains Is People

Nearly 60% of hospital CEOs report at least one unfilled senior executive position [7]. Leadership gaps are becoming as disruptive as frontline staffing shortages, with retirements accelerating and fewer clinicians pursuing traditional leadership pipelines [8]. The U.S. healthcare industry needs more than 4 million additional workers within five years [9] — but the scarcest resource isn't nurses or coders. It's the executives who can stitch together a clinical AI deployment, a payer negotiation, and an operational restructuring simultaneously.

The market is already pricing this in. When Fountain Health Partners launched this spring to back near-profitable healthcare startups with clear exit paths, co-founders Joey Campanelli and Jack Euston built their thesis around operational execution, not product novelty [10]. Their bet: in today's healthcare market, "operational execution matters much more than ambitious storytelling" [10]. Operational execution is a talent question, not a technology question.

The acqui-hire trend tells the same story. In Q1 2026, OpenAI acquired Torch and Headway picked up the Tezi team — both moves designed to bring talent, not technology, into digital health solutions [11].

The Validation Gap Makes This Harder

Here's the tension. AI is commoditizing fast, but clinical validation is not keeping pace. A systematic review found that only 5% of LLM studies in healthcare used real patient data; the vast majority relied on synthetic data or exam-style questions [12]. Another systematic review of LLMs deployed in live clinical workflows found just four qualifying studies [13]. The technology is racing ahead of the evidence, which means the leaders who can bridge that gap — who understand both the AI capability and the clinical reality — are worth more than the models themselves.

This is exactly where generic playbooks fail. Healthcare is unforgiving precisely because a product that works in a demo can crater against a real EHR integration, a real payer denial, or a real credentialing committee. The CEO who has navigated those minefields before is the asset that doesn't commoditize.

What This Means for Capital Allocation

Digital health startups raised $4 billion in Q1 2026, with average deal size climbing to $36.7 million — the highest since Q4 2021 [14]. But 59% of that capital was concentrated in just 12 mega-deals [14]. The market is active but selective, and it's selecting for companies that have already demonstrated operational execution, not just product promise.

The IPO window is cracking open following successful listings by Hinge Health and Omada Health, but policy uncertainty and volatile capital markets are making timing decisions difficult [15]. For companies eyeing exits, the question is no longer "is the product differentiated?" — most AI-enabled tools will converge. The question is whether the leadership team can navigate public-market scrutiny, regulatory headwinds, and operational scaling simultaneously.

Boston Scientific's $1.5 billion investment in MiRus for a 34% equity stake shows what strategic capital looks for: not just a product, but a team capable of executing a complex, regulated commercialization over multiple years [16].

The Board Question

If you're a healthcare CEO reading this, the operational implication is concrete. Your AI vendor selection matters less than it did eighteen months ago, because the vendors are converging. What matters is whether your leadership bench can deploy those tools into clinical workflows, manage the change, negotiate with payers who are also adopting AI, and hold the organization together through the transition.

If you're an investor, the diligence question shifts. The next pitch that opens with a proprietary model should prompt a follow-up: who on this team has sold into a health system before? Who has managed a denial rate? Who has sat across from a CMIO who doesn't want another dashboard?

AI is removing the product barrier and the service barrier. What it cannot remove is the leadership barrier. The companies that win the next five years will be the ones that treated talent as a capital investment — not a line item.